Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury.
Secondary brain damage after traumatic brain injury (TBI) involves neuro-inflammatory mechanisms that are mainly dependent on the intracerebral production of cytokines. Interleukin-6 (IL-6) may have a role both in the pathogenesis of neuronal damage and in the recovery mechanisms of injured neurons through the modulation of nerve growth factor (NGF) biosynthesis. However, the relationship between IL-6 and NGF expression and the severity and outcome of TBI remains controversial. We have conducted a prospective observational clinical study to determine whether the concentration of IL-6 and NGF in the cerebrospinal fluid (CSF) of children with TBI correlates with the severity of the injury and neurologic outcome of patients. CSF samples were collected from 29 children at 2 h (time T1) and 48 h (time T2) after severe TBI, and from 31 matched controls. TBI severity was evaluated by Glasgow Coma Scale (GCS) and neurologic outcome by Glasgow Outcome Score (GOS). CSF concentrations of IL-6 and NGF were measured by immunoenzymatic assays. Early NGF concentrations (T1) correlated significantly with head injury severity, whereas no correlation was found between GCS and IL-6. Furthermore, IL-6 and NGF upregulation after injury was associated with better neurologic outcomes. Based on these findings, we posit that NGF expression is a useful marker of brain damage following severe TBI. Moreover, the early upregulation of both IL-6 and NGF, which correlates with a favorable neurologic outcome, may reflect an endogenous attempt at neuroprotection in response to the damaging biochemical and molecular cascades triggered by traumatic insult.
Chiaretti
Antonio
A
Pediatric Intensive Care Unit, Catholic University Medical School, Rome, Italy. achiaretti@yahoo.it
Antonelli
Alessia
A
Mastrangelo
Antonio
A
Pezzotti
Patrizio
P
Tortorolo
Luca
L
Tosi
Federica
F
Genovese
Orazio
O
D000293:Adolescent; D015415:Biomarkers / Q000032:analysis / Q000134:cerebrospinal fluid; D001921:Brain / Q000378:metabolism* / Q000503:physiopathology; D001930:Brain Injuries / Q000134:cerebrospinal fluid* / Q000150:complications / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D019610:Cytoprotection / Q000502:physiology; D004660:Encephalitis / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D023261:Glasgow Outcome Scale; D006801:Humans; D007223:Infant; D015850:Interleukin-6 / Q000134:cerebrospinal fluid*; D008297:Male; D009410:Nerve Degeneration / Q000134:cerebrospinal fluid* / Q000209:etiology / Q000503:physiopathology; D020932:Nerve Growth Factor / Q000134:cerebrospinal fluid*; D009474:Neurons / Q000378:metabolism / Q000473:pathology; D011237:Predictive Value of Tests; D011379:Prognosis; D020127:Recovery of Function / Q000502:physiology; D013997:Time Factors; D015854:Up-Regulation / Q000502:physiology
D015415:Biomarkers; D015850:Interleukin-6; D020932:Nerve Growth Factor